2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
General media enquiries
Contact our global media and communications team at:
Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
Smiths Detection 3D X-ray technology deployed in £1bn Heathrow upgrade
Read our latest company news as Smiths Detection announces new Heathrow upgrade programme.
Find out more
John Crane hits 50 year dry gas seals anniversary
Read our latest news as John Crane celebrates a 50 year milestone for manufacturing dry gas seals
Find out more
John Crane signs global framework agreement with leading international energy company
Read our latest company news as John Crane signs a global framework agreement with a leading international energy company
Find out more